Immunotherapy · 2021
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis.
СтатьяПоддержка исследования: вне правительства СШАСистематический обзорNetwork Meta-AnalysisНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laukhtina Ekaterina, Mori Keiichiro, Mostafaei Hadi, Merseburger Axel S, Nyirady Peter, Moschini Marco, Quhal Fahad, Schuettfort Victor M, Pradere Benjamin, Motlagh Reza Sari, Enikeev Dmitry, Shariat Shahrokh F, Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group European Association
Аннотация
Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.